About Us

Board Members

Dr. David Sidransky

  • As a renowned oncologist and research scientist Dr. David Sidransky was named by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer.  Since 1994, he serves as the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. He is one of the most highly cited researchers in clinical and medical journals in the world, in the field of oncology during the past decade, with over 450 peer-reviewed publications. He has pioneered the detection of various molecular alterations in human cancer and bodily fluids and has developed markers for the detection and management of many human tumors. He is a founder of a number of biotechnology companies and holds numerous biotechnology patents and serves, and has served, as chairman, vice chairman, member of boards of directors and member of scientific advisory boards of a many distinguished companies. He also received numerous awards and honors, under which the 2004 Richard and Hinda Rosenthal Award from the American Association of Cancer Research and the Toby Comet Award Bar Ilan University in 2007.

Dr. Shmuel Cabilly

  • Dr. Shmuel Cabilly, holds a PhD in Immunology from the Hebrew university (1980). He spent four years in the US as a post-doctoral fellow heading a joint project of the City of Hope Research Institute and Genentech where he developed a new breakthrough technology for recombinant antibody production. This invention was patented worldwide. Today there are already more than 20 drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more. Dr Cabilly was also a co-founder and a chief scientist of Life technology Israel (formerly Ethrog Biotechnology) which was acquired by Invitrogen corp. (today Life technology). Dr. Cabilly is now an investor and a director of several companies.

Mr. Oliver Curme

  • Mr. Oliver D. Curme is a retired General Partner from  Battery Ventures. He joined the firm in 1985 and was based in the Boston office. Mr. Curme focused on investments in software and computing. He stepped down as a General Partner at Battery in 2006, after 20 years with the firm. Mr. Curme is also an advisor to TianDi Growth Capital in Shanghai.   He has over 25 years of venture capital experience, investing in numerous companies worldwide and facilitating technology transfer. Mr. Curme played a major role in institutionalizing Battery from 1998 to 2003, when he built and ran the software investment group of 20 investment professionals. He has made 28 investments, invested $155 million, realized (+value) $480 million, with an overall IRR of 41% and seven initial public offerings. Prior to joining Battery, Mr. Curme was a Lending Officer in the High Technology Division of First National Bank of Boston.   Mr. Curme holds an MBA from Harvard Business School and a B.S. in Biochemistry from Brown University.

Mr. Yuval Yanai

  • Yuval  has served as Chief Financial Officer of Given Imaging since September 1, 2005 until March 2014. From October 2000 through August 2005, he served as Senior Vice President and Chief Financial Officer of Koor Industries Ltd., one of Israel's largest holding corporations.  Prior to that, from April 1998 to September 2000 he served as Vice President and Chief Financial Officer of NICE Systems Ltd., an Israeli global provider of Insight from Interactions, and from 1991 to April 1998, he was the Vice President, Finance and Chief Financial Officer of Elscint Ltd., a former Israeli company engaged in the manufacturing of medical imaging devices that was acquired by larger companies in this field. He joined Elscint in 1985 and served as Corporate Controller and Corporate Treasurer through 1991. Mr. Yanai has served as a director of Makteshim-Agan Industries Ltd., Equity One, Inc., BVR Systems Ltd., Tadiran Communication Ltd., The Elisra Group and Telrad Networks Ltd. Mr. Yanai holds a B.Sc. in Accounting and Economics from the Tel Aviv University. Yuval serves  also as a member of the Board of Directors and the Chairman of the Audit Committee of Macrocure Ltd. (Nasdaq: MCUR )

Chaim Friedman

  • Chaim is an experienced business developer with over 20 years of hands-on involvement in growing technology companies. He co-founded STARLIMS, a global informatics provider and directed its financial and commercial operations including the company's 2007 Nasdaq IPO and subsequent $120 million acquisition by Abbott in 2010. Following the acquisition, Chaim joined Abbott to develop a scouting setup for new technologies and science originating from Israel’s growing biomed sector and academic community. Chaim recently founded LionBird, which provides early-stage financing and support to software, Internet and mobile startups. Chaim holds a B.Sc. degree in economics and management from the Technion – Israel Institute of Technology.

Boaz Shoham

Founder and Director
  • Mr. Boaz Shoham, an architect, founded Efranat LTD with Professor Yamamoto and Mr. Avi Levin. Mr. Boaz Shoham managed Efranat Ltd for two years as COO together with Mr. Avi Levin and is still active in the company.

Uri Yogev

CEO and Director
  • Prior to joining Efranat, Uri was the founder and CEO of Life Technologies Israel (formerly Ethrog Biotechnology) from its inception in 1993 until 2007. While serving as Ethrog's CEO, he conducted numerous development programs that yielded more than 60 different products in the Bio Research industry. He obtained an exclusive distribution agreement with Invitrogen Corp. (1996) and later led the acquisition of Ethrog by Invitrogen (today: Life Technology Nasdaq: LIFE). Uri designed and constructed a tailored and unique production facility and led the company to double digits $M in revenues with substantial profits. 

    Uri holds a BSc. in Life Sciences from the Tel Aviv University, Israel and an MBA from Northwestern University, IL and Tel Aviv University, Israel in the Kellogg Recanati program.

Back Up

News & Events

News & Events
  • Nov 2015

    Dr Talia Golan - Sheba hospital at AACR

    read more
  • Oct 2015

    Second expanded cohort of Phase I study

    read more
  • Sept 2015

    Dr. Rinat Rotem joined Efranat

    read more
  • Aug 2015

    Efranat's product name was changed

    read more
  • June 2015

    Phase I Dose Escalation completion

    read more